[go: up one dir, main page]

WO2014087367A3 - Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées - Google Patents

Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées Download PDF

Info

Publication number
WO2014087367A3
WO2014087367A3 PCT/IB2013/060667 IB2013060667W WO2014087367A3 WO 2014087367 A3 WO2014087367 A3 WO 2014087367A3 IB 2013060667 W IB2013060667 W IB 2013060667W WO 2014087367 A3 WO2014087367 A3 WO 2014087367A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compositions
disorders
methods
epilepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/060667
Other languages
English (en)
Other versions
WO2014087367A2 (fr
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2013/050740 external-priority patent/WO2013167986A2/fr
Application filed by Individual filed Critical Individual
Publication of WO2014087367A2 publication Critical patent/WO2014087367A2/fr
Publication of WO2014087367A3 publication Critical patent/WO2014087367A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule I ou leurs sels pharmaceutiquement acceptables, ainsi que des polymorphes, des solvates, des énantiomères, des stéréo-isomères et des hydrates de ceux-ci. Les compositions pharmaceutiques comprennent une quantité efficace de composés de formule I, et des procédés pour le traitement de maladies neurologiques peuvent être formulés pour une administration orale, buccale, rectale, topique, transdermique, transmucosale, intraveineuse, parentérale, un sirop ou une injection. De telles compositions peuvent être utilisées pour le traitement de l'épilepsie, de crises d'épilepsie, de maladies mentales, de troubles mentaux, de la schizophrénie, de la dépression, d'un trouble bipolaire, de la maladie d'Alzheimer, de l'anxiété, d'un trouble d'hyperactivité avec déficit de l'attention, de la démence, de troubles de l'humeur, d'un état de stress post-traumatique, de l'insomnie, de la migraine, de la psychose, d'un trouble obsessivo-compulsif, de l'autisme, de troubles d'anxiété, de la manie et de troubles cognitifs.
PCT/IB2013/060667 2012-12-09 2013-12-05 Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées Ceased WO2014087367A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN5123/CHE/2012 2012-12-09
IN5123CH2012 2012-12-09
INPCT/IB2013/050740 2013-01-29
PCT/IB2013/050740 WO2013167986A2 (fr) 2012-05-08 2013-01-29 Compositions et méthodes de traitement de l'épilepsie

Publications (2)

Publication Number Publication Date
WO2014087367A2 WO2014087367A2 (fr) 2014-06-12
WO2014087367A3 true WO2014087367A3 (fr) 2014-07-31

Family

ID=50884099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/060667 Ceased WO2014087367A2 (fr) 2012-12-09 2013-12-05 Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées

Country Status (1)

Country Link
WO (1) WO2014087367A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106511302B (zh) * 2015-09-11 2020-06-05 重庆润泽医药有限公司 一种释放度均匀性好的左旋奥拉西坦缓释胶囊及其制备方法
CN107510685B (zh) * 2016-06-15 2020-07-21 重庆润泽医药有限公司 一种含量均匀的(s)-4-羟基-2氧代-1-吡咯烷乙酰胺颗粒及其制备方法
CN107510681B (zh) * 2016-06-15 2020-07-03 重庆润泽医药有限公司 一种(s)-4-羟基-2氧代-1-吡咯烷乙酰胺颗粒及其制备方法
CN106955274B (zh) * 2016-07-13 2018-10-23 重庆润泽医药有限公司 一种(s)-4-羟基-2氧代-1-吡咯烷乙酰胺缓释胶囊及其制备方法
CN107625751B (zh) * 2016-07-14 2020-09-29 重庆润泽医药有限公司 一种稳定性好的左旋奥拉西坦缓释胶囊及其制备方法
CN106955275B (zh) * 2016-07-14 2018-10-26 重庆润泽医药有限公司 一种稳定性好的左旋奥拉西坦缓释胶囊及其制备方法
CN107661307A (zh) * 2016-07-26 2018-02-06 重庆润泽医药有限公司 一种收率高的(s)‑4‑羟基‑2氧代‑1‑吡咯烷乙酰胺缓释胶囊及其制备方法
CN108567751A (zh) * 2017-03-14 2018-09-25 重庆润泽医药有限公司 一种羟氧吡醋胺口腔崩解制剂及其制备方法
CN108567749A (zh) * 2017-03-14 2018-09-25 重庆润泽医药有限公司 一种适合儿童服用的左旋奥拉西坦口服制剂及其制备方法
CN109692166A (zh) * 2017-10-23 2019-04-30 重庆润泽医药有限公司 治疗癫痫的肠溶缓释颗粒及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145347A (en) * 1977-03-03 1979-03-20 Parke, Davis & Company N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidineacetamides
WO2001062726A2 (fr) * 2000-02-23 2001-08-30 Ucb, S.A. Derives de 2-oxo-1-pyrrolidine, procedes de preparation et utilisations desdits derives
WO2008075366A2 (fr) * 2006-12-20 2008-06-26 Medwell Laboratories Ltd. Nouveaux conjugués d'acides gras poly-insaturés avec des amines et utilisations thérapeutiques de ceux-ci
WO2010132693A2 (fr) * 2009-05-13 2010-11-18 Nektar Therapeutics Composés pyrrolidine contenant un oligomère
WO2010144712A1 (fr) * 2009-06-11 2010-12-16 Seradyn, Inc. Dérivés, réactifs et immuno-dosage pour détection du lévétiracétam
WO2011106688A1 (fr) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Conjugués de bis-acide gras et leurs utilisations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145347A (en) * 1977-03-03 1979-03-20 Parke, Davis & Company N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidineacetamides
WO2001062726A2 (fr) * 2000-02-23 2001-08-30 Ucb, S.A. Derives de 2-oxo-1-pyrrolidine, procedes de preparation et utilisations desdits derives
WO2008075366A2 (fr) * 2006-12-20 2008-06-26 Medwell Laboratories Ltd. Nouveaux conjugués d'acides gras poly-insaturés avec des amines et utilisations thérapeutiques de ceux-ci
WO2010132693A2 (fr) * 2009-05-13 2010-11-18 Nektar Therapeutics Composés pyrrolidine contenant un oligomère
WO2010144712A1 (fr) * 2009-06-11 2010-12-16 Seradyn, Inc. Dérivés, réactifs et immuno-dosage pour détection du lévétiracétam
WO2011106688A1 (fr) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Conjugués de bis-acide gras et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOYER M ET AL., EUR J PHARMACOL., vol. 286, no. 2, 14 November 1995 (1995-11-14), pages 137 - 146 *

Also Published As

Publication number Publication date
WO2014087367A2 (fr) 2014-06-12

Similar Documents

Publication Publication Date Title
WO2014087367A3 (fr) Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées
PH12013501556A1 (en) IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
HK1217486A1 (zh) 作爲β-分泌酶抑制剂的全氟化环丙基稠合的1，3-恶嗪-2-胺化合物以及其使用方法
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
TR201904614T4 (en) Novel pyrazole derivative.
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
CL2015000096A1 (es) Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
AR079103A1 (es) Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion
WO2014068463A3 (fr) Compositions et procédés de traitement d'une inflammation et de troubles métaboliques
IN2014DN09826A (fr)
MX2014006015A (es) Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1.
WO2014057439A3 (fr) Compositions et procédés de traitement de maladies neurologiques et des complications associées
WO2013175359A3 (fr) Compositions et méthodes pour le traitement de la sclérose en plaques
NZ603967A (en) 8-hydroxy-quinoline derivatives
WO2013167986A3 (fr) Compositions et méthodes de traitement de l'épilepsie
EA201690971A1 (ru) ПИРИДО[4,3-b]ПИРАЗИН-2-КАРБОКСАМИДЫ В КАЧЕСТВЕ НЕЙРОГЕННЫХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ РАССТРОЙСТВ
WO2014097137A3 (fr) Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques
FI3541784T3 (fi) Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina
WO2013167989A3 (fr) Compositions et méthodes de traitement de troubles neurologiques
NZ629855A (en) Sulphonamide derivatives of benzylamine for the treatment of cns diseases
WO2014060925A3 (fr) Compositions et méthodes de traitement de maladies neurologiques et neurodégénératives
WO2014195850A3 (fr) Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques
WO2013167999A3 (fr) Compositions et méthodes de traitement d'affections neurologiques
WO2014060941A3 (fr) Compositions d'agents neuroprotecteurs et procédés correspondants destinés au traitement de maladies neurologiques et neurodégénératives
PH12014502780A1 (en) Azetidine and piperidine compounds useful as pde10 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13861025

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13861025

Country of ref document: EP

Kind code of ref document: A2